Skip Navigation



Annals of Oncology Advance Access published online on October 26, 2005
Annals of Oncology, doi:10.1093/annonc/mdj047
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/2/200    most recent
mdj047v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vergote, I.
Right arrow Articles by Abram, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vergote, I.
Right arrow Articles by Abram, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received April 17, 2005
Revised September 10, 2005
Accepted September 12, 2005

review

Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents

I. Vergote 1* and P. Abram 2

1 University Hospitals, Leuven, Belgium
2 Belvoir Park Hospital, Belfast, UK

* To whom correspondence should be addressed.
I. Vergote, E-mail: Ignace.Vergote{at}uz.kuleuven.ac.be


  Abstract

Owing to its favourable tolerability profile versus cytotoxic chemotherapy, endocrine therapy is the treatment of choice for postmenopausal women with hormone receptor-positive advanced breast cancer (ABC). However, tolerability concerns associated with some endocrine treatments and the potential for cross-resistance has helped to drive the need for new, effective and better-tolerated agents. Fulvestrant is a new type of oestrogen receptor antagonist with no agonist effects. In phase III trials, fulvestrant has been shown to be at least as effective as the third-generation aromatase inhibitor (AI) anastrozole in the treatment of postmenopausal women with ABC progressing on prior tamoxifen therapy. Fulvestrant is administered as a once-monthly 250 mg intramuscular injection into the gluteus muscle. Here we review the tolerability of fulvestrant in the treatment of postmenopausal women with hormone-sensitive ABC and compare it with that of the four most frequently prescribed endocrine treatments for advanced disease (tamoxifen, anastrozole, letrozole and exemestane). Compared with these agents, fulvestrant is well tolerated and is associated with a lower incidence of joint disorders compared with the non-steroidal AIs and none of the potential androgenic side-effects that are sometimes seen with steroidal AIs. It is also associated with hot flushes compared with tamoxifen. Fulvestrant therefore provides clinicians and patients with a useful, well-tolerated option for the treatment of hormone-sensitive ABC. Integration of such agents into the endocrine treatment sequence may extend the opportunity for using well-tolerated therapies before chemotherapy needs to be considered and thus may improve quality of life for patients with ABC. The overall safety profiles of newer agents such as fulvestrant will become increasingly clear with their ongoing use.

Keywords: breast; breast cancer; fulvestrant; hormone; neoplasms; therapy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
J. F. R. Robertson, G. G. Steger, P. Neven, S. Barni, F. Gieseking, F. Nole, K. I. Pritchard, F. P. O'Malley, S. D. Simon, B. Kaufman, et al.
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Ann. Onc., October 29, 2009; (2009) mdp447v1.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Padron, L. Li, E. M. Kofoed, and F. Schaufele
Ligand-Selective Interdomain Conformations of Estrogen Receptor-{alpha}
Mol. Endocrinol., January 1, 2007; 21(1): 49 - 61.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L Perey, R Paridaens, H Hawle, K Zaman, F Nole, H Wildiers, M Fiche, D Dietrich, P Clement, D Koberle, et al.
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
Ann. Onc., January 1, 2007; 18(1): 64 - 69.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.